CASI CASI Pharmaceuticals, Inc. Stock Quote

CASI [NASD]

Index	-	P/E	-	EPS (ttm)	-2.25	Insider Own	4.70%	Shs Outstand	13.80M	Perf Week	-8.25%
Market Cap	37.42M	Forward P/E	-	EPS next Y	-1.51	Insider Trans	16.19%	Shs Float	11.55M	Perf Month	-25.07%
Income	-31.40M	PEG	-	EPS next Q	-0.56	Inst Own	1.80%	Short Float	1.42%	Perf Quarter	-60.62%
Sales	33.50M	P/S	1.12	EPS this Y	38.40%	Inst Trans	-16.25%	Short Ratio	2.51	Perf Half Y	-65.25%
Book/sh	5.44	P/B	0.51	EPS next Y	58.80%	ROA	-22.90%	Target Price	37.00	Perf Year	-81.47%
Cash/sh	2.79	P/C	1.00	EPS next 5Y	-	ROE	-36.80%	52W Range	2.69 - 17.40	Perf YTD	-65.25%
Dividend	-	P/FCF	-	EPS past 5Y	-9.70%	ROI	-50.50%	52W High	-84.31%	Beta	0.74
Dividend %	-	Quick Ratio	3.50	Sales past 5Y	-	Gross Margin	58.30%	52W Low	1.45%	ATR	0.40
Employees	168	Current Ratio	3.80	Sales Q/Q	59.60%	Oper. Margin	-	RSI (14)	36.10	Volatility	6.18% 6.53%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	44.00%	Profit Margin	-93.60%	Rel Volume	0.64	Prev Close	2.78
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 12 BMO	Payout	-	Avg Volume	65.47K	Price	2.73
Recom	1.30	SMA20	-10.59%	SMA50	-25.74%	SMA200	-64.19%	Volume	38,996	Change	-1.80%

May-18-21

Initiated

BTIG Research

Buy

Apr-26-21

Initiated

Mizuho

Buy

$3.80

Oct-23-20

Initiated

Oppenheimer

Outperform

Sep-22-16

Initiated

Maxim Group

Buy

Oct-29-15

Resumed

H.C. Wainwright

Buy

$2.50 → $3

Jun-23-15

Initiated

H.C. Wainwright

Buy

$2.50

Jun-02-22 06:34AM	CASI Pharmaceuticals stock falls after reverse split takes effect MarketWatch -8.69%
May-26-22 04:30PM	CASI PHARMACEUTICALS ANNOUNCES REVERSE STOCK SPLIT PR Newswire +11.56%
May-25-22 07:53AM	A CASI Pharmaceuticals, Inc. (NASDAQ:CASI) insider increased their holdings by 10% last year Simply Wall St. +12.49%
May-24-22 07:00AM	CASI PHARMACEUTICALS ENTERES INTO SUBLICENSE AGREEMENT WITH TIANSHI PHARMACEUTICALS FOR ANTI-CD38 MONOCLONAL ANTIBODY (MAB) CID-103 IN AUTOIMMUNE FIELD PR Newswire +9.28%
May-12-22 08:15AM	CASI Pharmaceuticals, Inc. (CASI) Reports Q1 Loss, Misses Revenue Estimates Zacks -5.92%
07:00AM	CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2022 FINANCIAL RESULTS PR Newswire
May-10-22 09:25AM	Corbus Pharmaceuticals (CRBP) Reports Q1 Loss, Lags Revenue Estimates Zacks
May-02-22 10:15AM	Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Invest In Growth? Simply Wall St.
07:00AM	CASI PHARMACEUTICALS TO REPORT FIRST QUARTER 2022 FINANCIAL RESULTS AND HOST CONFERENCE CALL MAY 12, 2022 PR Newswire
Apr-01-22 07:27AM	China Weighs Giving U.S. Full Access to Audits of Most Firms Bloomberg -12.81%
07:00AM	CASI PHARMACEUTICALS STATEMENT ON STATUS UNDER HOLDING FOREIGN COMPANIES ACCOUNTABLE ACT PR Newswire
Mar-31-22 07:15PM	Analysts Expect Breakeven For CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Before Long Simply Wall St. -8.99%
04:54AM	Baidu Added to SEC List of Firms Facing Possible Delisting Bloomberg
Mar-28-22 07:00AM	CASI PHARMACEUTICALS ANNOUNCES FULL-YEAR 2021 FINANCIAL RESULTS AND FOURTH QUARTER 2021 EVOMELA® REVENUE PR Newswire +7.03%
Mar-23-22 07:00AM	CASI PHARMACEUTICALS TO REPORT FOURTH QUARTER AND YEAR END 2021 FINANCIAL RESULTS AND HOST CONFERENCE CALL MARCH 28, 2022 PR Newswire
Mar-04-22 07:00AM	CASI PHARMACEUTICALS ANNOUNCES RENEWAL OF EXCLUSIVE DISTRIBUTION AGREEMENT FOR EVOMELA® IN CHINA PR Newswire
Feb-23-22 04:36AM	Shareholders in CASI Pharmaceuticals (NASDAQ:CASI) are in the red if they invested three years ago Simply Wall St.
Feb-16-22 07:00AM	CASI PHARMACEUTICALS ANNOUNCES PRELIMINARY FOURTH QUARTER AND FULL-YEAR 2021 REVENUES AND PROVIDES BUSINESS UPDATES PR Newswire
Feb-15-22 05:03PM	8 Medical Stocks to Buy According to Mitchell Blutts Consonance Capital Insider Monkey +11.05%
Jan-20-22 08:50AM	Casi Pharma-Partnered BioInvent's Lead Cancer Program Gets FDA Orphan Drug Tag Benzinga
07:00AM	CASI PHARMACEUTICALS PARTNER, BIOINVENT, ANNOUNCES BI -1206 GRANTED ORPHAN DRUG DESIGNATION BY THE U.S. FDA FOR THE TREATMENT OF PATIENTS WITH FOLLICULAR LYMPHOMA PR Newswire
Jan-18-22 07:00AM	CASI PHARMACEUTICALS ANNOUNCES CNCT19 (CD19 CAR-T) GRANTED ORPHAN DRUG DESIGNATION BY THE U.S. FDA PR Newswire -6.05%
Jan-09-22 07:28AM	How Many CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Shares Do Institutions Own? Simply Wall St.
Jan-03-22 07:00AM	CASI PHARMACEUTICALS, RECEIVES NASDAQ DEFICIENCY NOTICE PR Newswire +5.74%
Dec-17-21 07:00AM	CASI PHARMACEUTICALS ANNOUNCES STOCK REPURCHASE PROGRAM PR Newswire +12.71%
Dec-10-21 07:15AM	BioInvent and CASI Pharmaceuticals Announce CTA Approval for Clinical Studies of BI-1206 in NHL in China ACCESSWIRE
07:00AM	CASI PHARMACEUTICALS AND BIOINVENT ANNOUNCE CTA APPROVAL FOR CLINICAL STUDY OF BI-1206 IN NHL IN CHINA PR Newswire
Nov-25-21 04:34AM	Wei-Wu He Is The Chairman & CEO of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) And They Just Picked Up 7.8% More Shares Simply Wall St.
Nov-22-21 07:17AM	5 Penny Stocks Insiders Are Buying Benzinga
Nov-15-21 07:00AM	CASI Pharmaceuticals To Present At Jefferies London Healthcare Conference PR Newswire -5.56%
Nov-12-21 07:00AM	CASI Pharmaceuticals Announces Third Quarter 2021 Financial Results PR Newswire
Nov-05-21 07:00AM	CASI Pharmaceuticals Partner, BioInvent, To Present Further Positive Clinical Data On BI-1206 At ASH 2021 PR Newswire
Nov-02-21 07:00AM	CASI Pharmaceuticals To Report Third Quarter 2021 Financial Results And Host Conference Call November 12, 2021 PR Newswire
Nov-01-21 03:01PM	CASI Pharmaceuticals, Inc. (CASI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release Zacks
Oct-25-21 07:50AM	Despite Lacking Profits CASI Pharmaceuticals (NASDAQ:CASI) Seems To Be On Top Of Its Debt Simply Wall St.
07:00AM	CASI Pharmaceuticals Announces Partner Juventas Completion Of Series C Financing Of $63 Million (RMB410 Million) For Acceleration Of CNCT19 Pivotal Trials And Commercialization PR Newswire
Oct-06-21 07:17AM	CASI Pharma (CASI) Sees Hammer Chart Pattern: Time to Buy? Zacks
Sep-27-21 02:01PM	10 Best Biotech Stocks Under $10 Insider Monkey
Sep-20-21 07:00AM	CASI Pharmaceuticals, Inc. To Participate In Oppenheimer Fall Healthcare Life Sciences & MedTech Summit PR Newswire
Aug-23-21 09:58AM	4 Penny Stocks Insiders Are Buying Benzinga +23.26%
07:00AM	25 Stocks Moving in Monday's Pre-Market Session Benzinga
Aug-14-21 03:10AM	Upgrade: Analysts Just Made A Substantial Increase To Their CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Forecasts Simply Wall St.
Aug-12-21 10:05AM	CASI Pharmaceuticals, Inc. (CASI) Reports Q2 Loss, Tops Revenue Estimates Zacks
07:00AM	CASI Pharmaceuticals Announces Second Quarter 2021 Financial Results PR Newswire
Aug-10-21 07:00AM	CASI Pharmaceuticals To Report Second Quarter 2021 Financial Results And Host Conference Call August 12, 2021 PR Newswire
Aug-02-21 03:01PM	Analysts Estimate CASI Pharmaceuticals, Inc. (CASI) to Report a Decline in Earnings: What to Look Out for Zacks +6.90%
Jul-25-21 03:49AM	Could The CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Ownership Structure Tell Us Something Useful? Simply Wall St.
Jun-10-21 07:00AM	CASI Pharmaceuticals Announces Dosing Of First Patient Of CID-103 In Phase 1 Clinical Trial For Relapsed Or Refractory Multiple Myeloma PR Newswire
02:06AM	Need To Know: CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Insiders Have Been Buying Shares Simply Wall St.
May-27-21 07:00AM	CASI Pharmaceuticals, Inc. To Participate In Jefferies Virtual Healthcare Conference PR Newswire
May-17-21 10:20AM	INVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating CASI Pharmaceuticals, Inc. for Potential Breach of Fiduciary Duty Claims ACCESSWIRE
May-13-21 07:00AM	CASI Pharmaceuticals Announces First Quarter 2021 Financial Results PR Newswire
05:45AM	CASI Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
May-11-21 07:00AM	CASI Pharmaceuticals To Report First Quarter 2021 Financial Results And Host Conference Call May 13, 2021 PR Newswire
Apr-28-21 10:39AM	These 2 Penny Stocks Could Rally Over 100%, Says Oppenheimer TipRanks +11.56%
Apr-26-21 02:11AM	What Type Of Returns Would CASI Pharmaceuticals'(NASDAQ:CASI) Shareholders Have Earned If They Purchased Their Shares Three Years Ago? Simply Wall St. +8.93%
Mar-30-21 07:00AM	CASI Pharmaceuticals Announces Full Year 2020 Financial Results PR Newswire
Mar-24-21 03:57PM	Why CASI Pharmaceuticals Is Crashing Today Motley Fool -15.35%
08:30AM	CASI Pharmaceuticals Announces Pricing Of $32,500,000 Public Offering Of Common Stock PR Newswire
Mar-23-21 04:01PM	CASI Pharmaceuticals Announces Proposed Public Offering Of Common Stock PR Newswire
Mar-11-21 04:30PM	CASI Pharmaceuticals To Host Business Update Call March 12, 2021 PR Newswire
Mar-08-21 10:17AM	CASI Pharmaceuticals To Develop CB-5339 In Cancer Indications In China Benzinga
08:00AM	Cleave Therapeutics Licenses First-in-Class VCP/P97 Inhibitor CB-5339 To CASI Pharmaceuticals For Greater China Region PR Newswire
Feb-25-21 12:08AM	We're Hopeful That CASI Pharmaceuticals (NASDAQ:CASI) Will Use Its Cash Wisely Simply Wall St. -6.04%
Feb-16-21 07:00AM	CASI Pharmaceuticals Announces Preliminary Fourth Quarter And Full-Year 2020 Revenues And Provides Business Updates PR Newswire
Jan-28-21 07:00AM	CASI Pharmaceuticals Partner, BioInvent, Presents Phase I/IIA Data That Suggests BI-1206 Restores Activity Of Rituximab In Relapsed Non-Hodgkin's Lymphoma Patients PR Newswire
Jan-21-21 07:00AM	CASI Pharmaceuticals Partner, BioInvent, To Host Key Opinion Leader Call On BI-1206 For Relapsed Or Refractory Non-Hodgkin's Lymphoma PR Newswire
Jan-11-21 12:17AM	What Type Of Shareholders Make Up CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Share Registry? Simply Wall St.
Jan-08-21 07:00AM	CASI Pharmaceuticals, Inc. To Present At H.C. Wainwright Bioconnect Conference PR Newswire
Dec-23-20 07:00AM	CASI Pharmaceuticals Announces CNCT19 (CD19 CAR-T) Receives China Breakthrough Therapy Designation PR Newswire
Dec-16-20 07:00AM	CASI Pharmaceuticals Announces Appointment Of Chief Financial Officer PR Newswire
Dec-12-20 02:20PM	Is CASI A Good Stock To Buy Now? Insider Monkey
Nov-30-20 09:05AM	CASI: Raising target price on pipeline progress Zacks Small Cap Research
Nov-26-20 11:16PM	Chairman & CEO Wei-Wu He Just Bought 4.7% More Shares In CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Simply Wall St.
Nov-18-20 09:00PM	CASI Pharmaceuticals Announces Partner Juventas Completes $65 Million Financing And Initiates Registration Study For CNCT19 (CD19 CAR-T) PR Newswire
Nov-09-20 10:30PM	CASI Pharmaceuticals Inc (CASI) Q3 2020 Earnings Call Transcript Motley Fool
02:30PM	CASI Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
08:20AM	CASI Pharmaceuticals: Q3 Earnings Insights Benzinga
07:00AM	CASI Pharmaceuticals Announces Third Quarter 2020 Financial Results PR Newswire
Nov-06-20 06:14AM	How Many CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Shares Did Insiders Buy, In The Last Year? Simply Wall St.
Nov-05-20 07:00AM	CASI Pharmaceuticals To Report Third Quarter 2020 Financial Results And Host Conference Call November 9, 2020 PR Newswire
Oct-27-20 07:00AM	BioInvent licenses anti-FcRllB antibody BI-1206 to CASI Pharmaceuticals for Greater China region PR Newswire +17.22%
Oct-02-20 07:00AM	CASI Pharmaceuticals Announces Poster Presentation At The 2020 AABB Virtual Annual Meeting PR Newswire
Sep-29-20 07:00AM	CASI Pharmaceuticals Announces Restructuring of Partnership with Juventas Cell Therapy Ltd PR Newswire
Sep-11-20 07:00AM	CASI Pharmaceuticals, Inc. to Participate in Two Upcoming September Conferences PR Newswire
Sep-07-20 08:28AM	The CASI Pharmaceuticals (NASDAQ:CASI) Share Price Is Up 53% And Shareholders Are Holding On Simply Wall St.
Aug-26-20 05:31AM	CASI: A Change in Strategy Zacks Small Cap Research
Aug-11-20 11:30AM	CASI Pharmaceuticals Inc (CASI) Q2 2020 Earnings Call Transcript Motley Fool
Aug-10-20 07:29AM	CASI Pharmaceuticals: Q2 Earnings Insights Benzinga
07:00AM	CASI Pharmaceuticals Announces Second Quarter 2020 Financial Results PR Newswire
Jul-22-20 09:05AM	CASI Pharmaceuticals Announces Pricing Of $38,000,000 Public Offering Of Common Stock PR Newswire -14.80%
Jul-21-20 04:01PM	CASI Pharmaceuticals Announces Proposed Public Offering Of Common Stock PR Newswire
Jul-09-20 09:39AM	Here's What CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Shareholder Ownership Structure Looks Like Simply Wall St.
Jun-08-20 07:00AM	CASI Pharmaceuticals Announces Submission Of Clinical Trial Application (IND) To Conduct Phase 1 Study For Anti-38 Monoclonal Antibody Program PR Newswire
Jun-02-20 07:00AM	CASI Pharmaceuticals To Present At The Jefferies 2020 Healthcare Conference PR Newswire
May-31-20 05:38PM	Do Hedge Funds Love CASI Pharmaceuticals Inc (CASI)? Insider Monkey
May-25-20 06:14AM	Wei-Wu He Is The Chairman & CEO of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) And They Just Picked Up 32% More Shares Simply Wall St.
May-14-20 06:47AM	Earnings Update: CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Just Reported And Analysts Are Boosting Their Estimates Simply Wall St.
May-12-20 06:43AM	Upgrade: Analysts Just Made A Notable Increase To Their CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Forecasts Simply Wall St.
May-11-20 07:00AM	CASI Pharmaceuticals Announces First Quarter 2020 Financial Results PR Newswire

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase I/IIa trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome. Its product pipeline also comprises CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; and Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors. The company has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
He Wei-Wu	Chairman and CEO	Jun 15	Buy	3.18	50,000	159,000	644,553	Jun 17 04:14 PM
He Wei-Wu	Chairman and CEO	Jun 14	Buy	3.06	2,096	6,414	594,553	Jun 17 04:14 PM
He Wei-Wu	Chairman and CEO	Jun 13	Buy	2.97	36,058	107,092	592,457	Jun 17 04:14 PM
He Wei-Wu	Chairman and CEO	Nov 18	Buy	0.98	200,000	196,000	5,558,472	Nov 19 04:10 PM
He Wei-Wu	Chairman and CEO	Nov 17	Buy	0.99	200,000	198,000	5,362,569	Nov 19 04:10 PM
He Wei-Wu	Chairman and CEO	Aug 19	Buy	1.26	180,000	226,800	5,163,994	Aug 20 04:27 PM
He Wei-Wu	Chairman and CEO	Aug 18	Buy	1.29	300,000	387,000	4,983,994	Aug 20 04:27 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience